Restricted accessResearch articleFirst published online 2025-10
Cognitive performance and blood biomarkers: Insights into their relationship and predicting high Amyloid Probability Score in cognitively impaired older adults
Understanding associations between cognitive performance and blood biomarkers supports diagnosis and treatment of Alzheimer's disease (AD); however, this relationship remains unclear.
Objective
Exploring associations between the Amyloid Probability Score (APS; PrecivityAD® blood test) and cognitive performance, and between Mini-Mental State Examination (MMSE) and Cogstate Brief Battery (CBB) in cognitively impaired older adults.
Methods
Older adults aged ≥ 60 years with MMSE from 10 to 27, recruited from a cohort in Japan, were assessed with the CBB, and plasma biomarkers to calculate APS. We used Spearman correlation to explore relationships; receiver operating curves and cross-validation to identify the best model for predicting high APS.
Results
Among 46 participants (mean age = 78.3 ± 5.9; mean MMSE = 20.3 ± 4.6), 39.1% did not complete at least one test in the CBB. Lower MMSE were observed in those who were non-completers. MMSE correlated with Detection (Psychomotor function), Identification (Attention), and their composite (r = 0.34−0.52; p < 0.05; 95%CI excluding null value). Higher APS was seen in those who did not complete the One Card Learning (OCL-visual learning and short-term memory). The best model for predicting High APS included OCL completion status, MMSE and Years of Education, achieving accuracy = 0.808 and kappa = 0.606 in participants with MMSE < 21.
Conclusions
Our findings suggest a consideration of incompletion when using CBB in cognitively impaired older adults and a potential approach to differentiate High APS group among those with moderate to severe dementia based on visual learning and short-term memory, global cognition and education level.
Sosa-OrtizALAcosta-CastilloIPrinceMJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res2012; 43: 600–608.
3.
KinoshitaSKishimotoT. Dementia in Japan: a societal focus. Lancet Neurol2023; 22: 1101–1102.
4.
GaleSAAcarDDaffnerKR. Dementia. Am J Med2018; 131: 1161–1169.
5.
RiedererF. Donanemab in early Alzheimer’s disease. J Neurol Neurochir Psychiatr2021; 22: 142–143.
6.
JackCRAndrewsJSBeachTG, et al.Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement2024; 20: 5143–5169.
7.
SchindlerSEBatemanRJ. Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia. Nat Aging2021; 1: 26–28.
8.
SchindlerSEBollingerJGOvodV, et al.High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology2019; 93: E1647–E1659.
9.
VerberkIMWSlotREVerfaillieSCJ, et al.Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol2018; 84: 648–658.
10.
KirmessKMMeyerMRHolubaschMS, et al.The PrecivityADTM test: accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta2021; 519: 267–275.
11.
HuYKirmessKMMeyerMR, et al.Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. JAMA Netw Open2022; 5: E228392.
12.
FogelmanIWestTBraunsteinJB, et al.Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. Ann Clin Transl Neurol2023; 10: 765–778.
13.
KoskiLBrouilletteMJLalondeR, et al.Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment. HIV Med2011; 12: 472–480.
14.
ParseyCMSchmitter-EdgecombeM. Applications of technology in neuropsychological assessment. Clin Neuropsychol2013; 27: 1328–1361.
15.
FillitHMSimonESDonigerGM, et al.Practicality of a computerized system for cognitive assessment in the elderly. Alzheimers Dement2008; 4: 14–21.
16.
OssenkoppeleRSmithROhlssonT, et al.Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology2019; 92: e601–e612.
17.
DoraiswamyPMSperlingRAJohnsonK, et al.Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry2014; 19: 1044–1051.
18.
TannerJAIaccarinoLEdwardsL, et al.Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease. Brain2022; 145: 4489–4505.
19.
AschenbrennerAJGordonBABenzingerTLS, et al.Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology2018; 91: e859–e866.
20.
NakamuraTKawarabayashiTSeinoY, et al.Aging and APOE-ε4 are determinative factors of plasma Aβ42 levels. Ann Clin Transl Neurol2018; 5: 1184–1191.
21.
SunQNiJWeiM, et al.Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals. Front Aging Neurosci2022; 14: 963845.
22.
XiaoZWuXWuW, et al.Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease. Alzheimers Res Ther2021; 13: 123.
23.
SapkotaSEricksonKHarveyD, et al.Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: mediation with hippocampal volume. Alzheimers Dement (Amst)2022; 14: e12349.
24.
ChenTBLaiYHKeTL, et al.Changes in plasma amyloid and tau in a longitudinal study of normal aging, mild cognitive impairment, and Alzheimer’s disease. Dement Geriatr Cogn Disord2020; 48: 180–195.
25.
SanchezEWilkinsonTCoughlanG, et al.Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario neurodegenerative disease research initiative. Alzheimers Dement2024; 20: 1753–1770.
26.
TsaiCLLiangCSLeeJT, et al.Associations between plasma biomarkers and cognition in patients with Alzheimer’s disease and amnestic mild cognitive impairment: a cross- sectional and longitudinal study. J Clin Med2019; 8: 1893.
27.
PereiraJBJanelidzeSStomrudE, et al.Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain2021; 144: 2826–2836.
28.
ChouliarasLThomasAMalpettiM, et al.Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry2022; 93: 651–658.
29.
TonioloSZhaoSScholczA, et al.Relationship of plasma biomarkers to digital cognitive tests in Alzheimer’s disease. Alzheimers Dement (Amst)2024; 16: e12590.
30.
IkangaJPatelSSRobertsBR, et al.Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo. Alzheimers Dement (Amst)2023; 15: e12496.
31.
MaruffPLimYYDarbyD, et al.Clinical utility of the Cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer’s disease. BMC Psychol2013; 1: 30.
32.
LimYYVillemagneVLLawsSM, et al.Performance on the Cogstate brief battery is related to amyloid levels and hippocampal volume in very mild dementia. J Mol Neurosci2016; 60: 362–370.
33.
de JagerCASchrijnemaekersACMCHoneyTEM, et al.Detection of MCI in the clinic: evaluation of the sensitivity and specificity of a computerised test battery, the hopkins verbal learning test and the MMSE. Age Ageing2009; 38: 455–460.
CiesielskaNSokołowskiRMazurE, et al.Is the Montreal cognitive assessment (MoCA) test better suited than the Mini-mental state examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol2016; 50: 1039–1052.
36.
CreavinSTWisniewskiSNoel-StorrAH, et al.Mini-Mental state examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev2016; 2026: CD011145.
37.
PerneczkyRWagenpfeilSKomossaK, et al.Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry2006; 14: 139–144.
38.
LimYYJaegerJHarringtonK, et al.Three-month stability of the Cogstate brief battery in healthy older adults, mild cognitive impairment, and Alzheimer’s disease: results from the Australian imaging, biomarkers, and lifestyle-rate of change substudy (AIBL-ROCS). Arch Clin Neuropsychol2013; 28: 320–330.
39.
HammersDSpurgeonERyanK, et al.Reliability of repeated cognitive assessment of dementia using a brief computerized battery. Am J Alzheimers Dis Other Demen2011; 26: 326–333.
40.
KatajaELKarlssonLTolvanenM, et al.Correlation between the Cogstate computerized measure and WAIS-IV among birth cohort mothers. Arch Clin Neuropsychol2017; 32: 252–258.
41.
YoshidaTSugaMArimaK, et al.Criterion and construct validity of the Cogstate schizophrenia battery in Japanese patients with schizophrenia. PLoS One2011; 6: e20469.
42.
WhiteJPSchembriAPrenn-GolograncC, et al.Sensitivity of individual and composite test scores from the Cogstate brief battery to mild cognitive impairment and dementia due to Alzheimer’s disease. J Alzheimers Dis2023; 96: 1781–1799.
43.
HarringtonKDLimYYAmesD, et al.Using robust normative data to investigate the neuropsychology of cognitive aging. Arch Clin Neuropsychol2017; 32: 142–154.
44.
LimYYEllisKAHarringtonK, et al.Use of the CogState brief battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian imaging, biomarkers and lifestyle (AIBL) study. J Clin Exp Neuropsychol2012; 34: 345–358.
45.
RacineAMClarkLRBermanSE, et al.Associations between performance on an abbreviated CogState battery, other measures of cognitive function, and biomarkers in people at risk for Alzheimer’s disease. J Alzheimers Dis2016; 54: 1395–1408.
46.
CowanNBaoCBishop-ChrzanowskiBM, et al.The relation between attention and memory. Annu Rev Psychol2024; 75: 183–214.
47.
ChunMMTurk-BrowneNB. Interactions between attention and memory. Curr Opin Neurobiol2007; 17: 177–184.
48.
MackinRSInselPSTruranD, et al.Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: results from the brain health registry. Alzheimers Dement (Amst)2018; 10: 573–582.
49.
WangXBakulskiKMKarvonen-GutierrezCA, et al.Blood-based biomarkers for Alzheimer’s disease and cognitive function from mid- to late life. Alzheimers Dement2024; 20: 1807–1814.
50.
StevensDAWorkmanCIKuwabaraH, et al.Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment. Brain Commun2022; 4: fcac016.
51.
RosselliMUribeIVAhneE, et al.Culture, ethnicity, and level of education in Alzheimer’s disease. Neurotherapeutics2022; 19: 26–54.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
